Showing 1991-2000 of 3223 results for "".
- Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directorshttps://modernod.com/news/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-directors/2479051/Second Sight Medical Products announced that the company’s Board of Directors has appointed two new members, Dean Baker, PhD, and Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to add these two very talented individuals
- Jasmine Pachnanda Named Senior Vice President for CEO Leadership Alliance; Will Lead SoCal AI Initiativehttps://modernod.com/news/jasmine-pachnanda-named-senior-vice-president-for-ceo-leadership-alliance-will-lead-socal-ai-initiative/2479012/The CEO Leadership Alliance – Orange County (CLA-OC) has named Jasmine Pachnanda as Senior Vice President. Ms. Pachnanda will work with a range of partners and stakeholders, harnessing efforts to grow and demonstrate Southern California’s emerging leadership as a worldwide center for
- Johnson & Johnson Vision Receives Approval in Japan for First Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/Johnson & Johnson Vision announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the first and only vision correction contact lens that relieves allergic eye itch: Acuvue Theravision with Ketotifen. The lens contains ketotifen, an H1 histamine receptor antagonis
- New Study Links Protein Causing Alzheimer’s Disease With Common Sight Losshttps://modernod.com/news/new-study-links-protein-causing-alzheimers-disease-with-common-sight-loss/2478957/Newly published research has revealed a close link between proteins associated with Alzheimer’s disease and age-related sight loss. The findings could open the way to new treatments for patients with deteriorating vision and through this study, scientists believe they could reduce the need for us
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T
- Allergan Launches Glaucoma in Perspective Apphttps://modernod.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/Allergan has announced the launch of Glaucoma in Perspective (GiP), an app designed to help patients understand the impact of glaucoma, improve quality of life, and reduce disease progression by promoting treatment adherence. The GiP app has been produced and funded by Allergan, with consu
- CorNeat Vision Partners with LiveU and Alcon for Remote Surgeon Virtual Presencehttps://modernod.com/news/corneat-vision-partners-with-liveu-and-alcon-for-remote-surgeon-virtual-presence/2478949/CorNeat Vision and LiveU, a provider of live video streaming and remote production solutions, announced that they have partnered and implemented an on-demand Remote Surgeon Virtual Presence (RSVP) solution. The companies cooperated with Alcon to leverage its NGENUITY 3D Visualization Syste
- Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patientshttps://modernod.com/news/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients/2478948/Alteogen announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened compet
- Allergan Submits New Drug Application for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-submits-new-drug-application-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478915/Allergan announced that it has submitted a new drug application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021. The NDA is based primarily on data from two phase 3 G
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu